Look for M&A activity—big and small—a pair of breakthrough drugs and the prospect of government price controls.   Read More

Roche originally offered $89 a share. Genentech said that was too low. Since then both sides have been playing their hands very close to the vest. The dollar has gone up and the Swiss franc has gone down, so the value of the deal is already higher even if Roche didn't up the ante.    Read More

Following are the day’s biggest winners and losers. Find out why shares of Apple and Genetech popped while Google and Campbell Soup dropped.   Read More

As the market remains focused on Citi and the President-elect's midday cabinet announcement there are a few newsworthy things going on in biopharmaland.    Read More

When drug companies choose bullish, optimistic-sounding acronyms for clinical trials they should, perhaps, choose more wisely lest they backfire when the tests don't turn out like they hope they will. Witness what happened this morning to AstraZeneca.    Read More

Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!   Read More

Genentech investors who were hoping Roche would shed a little more light on the status of its proposed acquisition of the biotech giant might have hung up from the Swiss drugmaker's conference call a little disappointed.    Read More

Despite a slowing economy, drug stocks such as Abbott Labs and Genentech posted positive earnings reports. Is health care the best defensive play in this market?   Read More

As we head into the weekend (TGIF, right?), I wanted to clean out the ol' inbox.   Read More

Looking for new investment options. Check out these strategies.   Read More